Last reviewed · How we verify
VisuXL®
At a glance
| Generic name | VisuXL® |
|---|---|
| Also known as | VisuXL tear drop |
| Sponsor | Adolfo Daniel Rodriguez-Carrizalez |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Quantum Molecular Resonance Combined With Intense Pulsed Light in Mixed Dry Eye (NA)
- Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy (PHASE2)
- Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED (NA)
- Evaluation of the VisuXL® Performance on Ocular Surface Discomfort (NA)
- Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry Eye (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VisuXL® CI brief — competitive landscape report
- VisuXL® updates RSS · CI watch RSS
- Adolfo Daniel Rodriguez-Carrizalez portfolio CI